万博manbetx 体育官网atossa治疗方法设置为包含在拉塞尔2000和罗素3000索引中

atossa标志

PDF.打印查看全部
万博manbetx 体育官网atossa治疗方法设置为包含在拉塞尔2000和罗素3000索引中

西雅图,2021年6月16日 - Atossa 万博manbetx 体育官网Therapeutics,Inc。(纳斯达克:ATOS),临床舞台舞台生物制药公司,寻求发现和开发创新的药物,在显着的未满足医疗需求领域,目前的乳腺癌和Covid-19今天万博体育怎么买足彩announced it is set to be added to the Russell 2000 and Russell 3000 Indexes This milestone will take place at the conclusion of the 2021 Russell Indexes’ annual reconstitution, effective after the U.S. market opens on June 28, 2021, according to a preliminary list of additions posted June 4, and June 14, 2021.

“Atossa’s inclusion in both the Russell 2000 and Russell 3000 Indexes present an important opportunity for us to further expand Atossa’s awareness among a broader group of investors, which we expect will also further enhance its liquidity,” said Kyle Guse, Atossa’s CFO and General Counsel.

Russell 2000和Russell 3000索引中的成员资格,每个指数仍然在一年内到位,意味着在适当的增长和价值样式指标中自动包容。FTSE Russell主要通过客观,市场 - 大写排名和风格属性来确定其罗素指标的成员资格。

罗素指标被投资经理和机构投资者广泛用于指数基金,并作为积极投资策略的基准。欧冠直播万博体育b约有10.6万亿美元的资产是针对罗素的美国指数的基准测试。Russell索引是一个领先的全球索引提供商FTSE Russell的一部分。

关于Atos万博manbetx 体育官网sa治疗学

万博manbetx 体育官网Atossa Therapeutics,Inc。是一家临床阶段的生物制药公司,寻求发现和开发创新的药物,在明显的未满足医疗需求中,目前对乳腺癌和Covid-19的专注。万博体育怎么买足彩有关更多信息,请访问www.www.compemergency.com.

前瞻性陈述免责声明声明

在本新闻稿中的前瞻性陈述,atossa承诺更新义务,可能会受风险和不确定性,可能导致实际结果与预期或估计的未来成果不同,包括但不限于有关关闭的满意与提供的提供和预期使用的条件以及与FDA的临时和最终临床结果,行动和不合作之间的任何变化相关的情况,风险和不确定性,由ATOSSA所需的监管批准的结果或时机包括所需的到commence studies of AT-H201, AT-301 and Endoxifen, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa’s products, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others such as patent rights, whether reduction in Ki-67 or any other result from a neoadjuvant study is an approvable endpoint for oral Endoxifen, and other risks detailed from time to time in Atossa’s filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

公司联系人:
万博manbetx 体育官网Atossa Therapeutics,Inc。
凯尔格苏,CFO和一般律师
办公室:866 893-4927
kyle.guse@atossainc.com.

投资者关系联系:
C矿石红外
办公室:(516)222-2560
r @ atossainc.com.


主要徽标

2021年6月16日

隐私

字体调整大小